{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:12:49Z","timestamp":1792642369149,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/ftd.0000000000000015","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T11:31:43Z","timestamp":1387279903000},"page":"302-309","source":"Crossref","is-referenced-by-count":28,"title":["Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy"],"prefix":"10.1097","volume":"36","author":[{"given":"Junji","family":"Saruwatari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ogusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Shimomasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takateru","family":"Ishitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210129","first-page":"673","article-title":"Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.","volume":"7","author":"Leahy","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/14656566.2012.647686","article-title":"Clobazam for treatment of epilepsy.","volume":"13","author":"Giarratano","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s40263-012-0007-0","article-title":"Clobazam: in patients with Lennox-Gastaut syndrome.","volume":"26","author":"Yang","year":"2012","journal-title":"CNS Drugs"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":". Clobazam in the treatment of Lennox-Gastaut syndrome.","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","article-title":". Pharmacokinetics of single and multiple doses of clobazam in humans.","volume":"7","author":"Rupp","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF00542148","article-title":". Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage.","volume":"26","author":"Ochs","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-5-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jchromb.2005.06.031","article-title":". Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.","volume":"823","author":"Rouini","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","article-title":"Clobazam.","volume":"4","author":"Ng","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":". In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.","volume":"35","author":"de Leon","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R11-5-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on therapeutic strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","article-title":". Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.","volume":"50","author":"Man","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R13-5-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","article-title":"Population differences in major functional polymorphisms of pharmacokineticspharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.","volume":"27","author":"Kurose","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","article-title":". A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.","volume":"26","author":"Kosaki","year":"2004","journal-title":"Brain Dev"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/14622416.9.5.527","article-title":". Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.","volume":"9","author":"Seo","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.mce.2010.10.022","article-title":". Consequences of POR mutations and polymorphisms.","volume":"336","author":"Miller","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1073\/pnas.0711621105","article-title":". Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.","volume":"105","author":"Huang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-5-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-4347(00)00391-1","article-title":"Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis.","volume":"750","author":"Kunicki","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R19-5-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1375\/twin.11.3.249","article-title":"A century of Hardy-Weinberg equilibrium.","volume":"11","author":"Mayo","year":"2008","journal-title":"Twin Res Hum Genet"},{"key":"R20-5-20210129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","article-title":". The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.","volume":"19","author":"Oneda","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R21-5-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002280050442","article-title":". Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.","volume":"54","author":"Nakasa","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-5-20210129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/dmd.31.3.282","article-title":". Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices.","volume":"31","author":"Edwards","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R23-5-20210129","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":". CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R24-5-20210129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","article-title":". Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man.","volume":"11","author":"Levy","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"R25-5-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0090-9556(25)08481-8","article-title":". Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.","volume":"24","author":"Bajpai","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"R26-5-20210129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":". Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.","volume":"29","author":"Goto","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R27-5-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","article-title":". Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.","volume":"14","author":"Sennoune","year":"1992","journal-title":"Ther Drug Monit"},{"key":"R28-5-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3851\/IMP1953","article-title":". A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.","volume":"17","author":"Naccarato","year":"2012","journal-title":"Antivir Ther"},{"key":"R29-5-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.forsciint.2004.03.029","article-title":". Forensic intoxication with clobazam: HPLCDADMSD analysis.","volume":"143","author":"Proenca","year":"2004","journal-title":"Forensic Sci Int"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:21:37Z","timestamp":1746080497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201406000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000015","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}